Patient‐derived Immunocompetent Tumor Organoids: A Platform for Chemotherapy Evaluation in the Context of T‐cell Recognition

Most of the anticancer compounds synthesized by chemists are primarily evaluated for their direct cytotoxic effects at the cellular level, often overlooking the critical role of the immune system. In this study, we developed a patient‐derived, T‐cell‐retaining tumor organoid model that allows us to...

Ausführliche Beschreibung